ibrutinib
Selected indexed studies
- Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities. (NEJM Evid, 2022) [PMID:38319255]
- Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. (N Engl J Med, 2018) [PMID:30501481]
- Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. (Lancet Oncol, 2025) [PMID:39914418]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities. (2022) pubmed
- Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. (2018) pubmed
- Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. (2025) pubmed
- Ibrutinib alleviates LPS-induced neuroinflammation and synaptic defects in a mouse model of depression. (2021) pubmed
- Ibrutinib suppresses LPS-induced neuroinflammatory responses in BV2 microglial cells and wild-type mice. (2018) pubmed
- Ibrutinib and venetoclax combination therapy for mantle cell lymphoma: are two better than one? (2024) pubmed
- Ibrutinib: Pediatric First Approval. (2023) pubmed
- Ibrutinib-Associated Cardiotoxicity: From the Pharmaceutical to the Clinical. (2022) pubmed
- Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. (2022) pubmed
- Ibrutinib-Associated Atrial Fibrillation. (2018) pubmed